Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,518 across all filing types
Latest filing 2024-05-17 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-Beta Klotho MONOCLONAL ANTIBODY DRUG (JMT202) OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new drug by the National Medical Products Administration of China. It is an announcement of a regulatory milestone related to product development, not a financial report, management change, or shareholder meeting material. The document is relatively short (2554 characters) and does not contain financial data, earnings, or detailed management discussion. It is not a report but an announcement of a significant event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-05-17 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve the unaudited first quarterly results for the three months ended 31 March 2024. It does not contain any financial data or detailed report content itself, but merely announces the upcoming board meeting and the intention to approve quarterly results. The document length is only 1294 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the rules, such announcements about upcoming board meetings and report approvals are best classified as Regulatory Filings (RNS) because they do not contain substantive financial data or the report itself.
2024-05-14 English
VOLUNTARY ANNOUNCEMENT - PERAMIVIR INJECTION OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the drug registration approval of Peramivir Injection by the National Medical Products Administration of China. It is a short announcement (1972 characters) that informs the market about a regulatory approval event. There is no financial data, no detailed report, no meeting materials, no voting results, no management discussion, no earnings information, and no mention of any report being attached or published. The content is a regulatory announcement about a product approval, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a certification or officer attestation. Given the nature and length, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-05-14 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Next Day Disclosure Return' for an equity issuer, specifically CSPC Pharmaceutical Group Limited. It details changes in issued share capital and share buybacks, including repurchase of shares and updated issued share counts. The document references compliance with the Stock Exchange of Hong Kong Listing Rules, specifically rules related to disclosure of changes in issued share capital. The content is focused on reporting share capital changes and repurchases, not on financial results, management changes, or other report types. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes. The document length is over 6,000 characters and contains substantive data on share capital changes, so it is not a mere announcement or certification. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2024-05-03 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 April 2024. It details movements in issued shares, share options exercised, repurchases, and other share capital changes. It is submitted to the Hong Kong Exchanges and Clearing Limited and includes specific data on share capital changes, share options exercised, and repurchases. The document is a regulatory submission reporting share capital movements for a specific month, consistent with a regulatory filing under exchange rules rather than a financial report or announcement of a report. It is not an annual or interim report, earnings release, or proxy statement. It is not a report publication announcement since it contains substantive data. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-05-02 English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Transaction in Own Shares Classification · 100% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the purchase of shares on the market pursuant to its Share Award Scheme. It details the number of shares purchased, the average price, total consideration, and the balance of shares held by the trustee. There is no financial statement, earnings data, or detailed report content. The document is an announcement about share purchases related to a share award scheme, which fits the category of Transaction in Own Shares (POS). The document length is short (2324 characters), and it is not a report publication or certification. Therefore, the appropriate classification is POS.
2024-04-26 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.